Drug combo ups breast cancer survival-study

	Tweet

The combination of the anti-cancer drugs Herceptin and Taxotere appears to work better than Taxotere alone in women with advanced breast cancer that has spread beyond the breast, research shows. Moreover, there is little added toxicity when Herceptin is given.

Herceptin (trastuzumab) is a monoclonal antibody, meaning that it binds to one specific protein, HER2, which helps regulate cell growth. Overexpression of HER2, a sign of more aggressive cancer, occurs in about 25 percent to 30 percent of breast tumors. Taxotere (docetaxel) is a chemotherapy drug widely used to treat breast cancer and other cancers as well.

Previous studies indicate “synergy” between the two agents in women with breast cancer. To investigate further, Dr. Michel Marty, from Innovative Therapeutics in Paris, and colleagues treated 186 women with HER2-positive advanced breast cancer with six cycles of Taxotere with or without Herceptin.

Women treated with the combination regimen had a higher response rate (61 percent vs. 34 percent) and survived significantly longer (31.2 vs. 22.7 months) than women given Taxotere alone.

These findings, along with previous findings, support the use of Herceptin with a taxane such as Taxotere as first-line therapy for HER2-positive advanced breast cancer, the researchers conclude in the Journal of Clinical Oncology.

Overall, the number and severity of side effects seen in both groups were similar, aside from a higher incidence of neutropenia in the combination group. Neutropenia is a condition characterized by a drop in infection-fighting white blood cells that can occur with frequent chemotherapy.

Cardiac toxicity with Herceptin and Taxotere combination therapy, a concern in earlier trials, is “manageable,” the authors conclude, based on the low incidence of heart problems seen in women in the study.

In a commentary, Drs. Charles L. Vogel and Elizabeth Tan-Chiu, from the Cancer Research Network in Plantation, Florida, comment that while they “fully endorse” first-line Herceptin in these women, “a lingering question” remains regarding the survival benefit of Herceptin combination therapy compared with a sequential treatment approach.

SOURCE: Journal of Clinical Oncology, July 1, 2005. 

RELATED STORIES:
Pregnancy drug doubles risk of breast cancer   Women new to HT had no increased risk of breast cancer   Researchers develop a new cell and animal model of inflammatory breast cancer   Breast cancer doesn’t have to mean losing your breast   Gene screen for breast cancer better than pathologist’s “eye”   Error rate higher in breast imaging reports generated by automatic speech recognition   How BRCA1 Mutations Cause Breast Cancer Revealed for First Time   Family, Friends May Impact Breast Cancer Surgery Decision   Contrast agent puts new light on diagnosing breast cancer   Researchers Identify Risk Factors for Contralateral Breast Cancer   Few Surgeons Routinely Refer Breast Cancer Patients for Reconstruction   Exercise boosts breast cancer patients’ well-being   Discovery suggests location of genes for breast density, a strong risk factor for breast cancer   Minorities less likely to know about breast cancer options   New Insight into the Biology of the BRCA1 Breast Cancer Gene   Landmine detection technology adapted to screen for breast cancer   Cell Study Finds Receptor Can Fight Tamoxifen-resistant Breast Cancer Cells   Racial disparities seen in male breast cancer survival   Mammograms may be worth risks for some in their 40s   Dense breasts linked to return of breast cancer   Breast cancer treatment knowledge lacking   Most breast cancers not linked to ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]